There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bio-Techne Corporation (NASDAQ:TECH) and Antares Pharma (NASDAQ:ATRS) with bullish sentiments.
Bio-Techne Corporation (TECH)
Argus Research analyst John Staszak maintained a Buy rating on Bio-Techne Corporation today and set a price target of $230. The company’s shares closed yesterday at $203.80, close to its 52-week high of $206.04.
According to TipRanks.com, Staszak is a 4-star analyst with an average return of 10.0% and a 62.2% success rate. Staszak covers the Services sector, focusing on stocks such as Lululemon Athletica Inc, WellCare Health Plans, and Southwest Airlines.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bio-Techne Corporation with a $201.20 average price target.
See today’s analyst top recommended stocks >>
Antares Pharma (ATRS)
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Antares Pharma, with a price target of $5.30. The company’s shares closed yesterday at $3.26.
According to TipRanks.com, Wilbur is a 4-star analyst with an average return of 4.3% and a 49.0% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Mallinckrodt, Allergan, and Lannett.
Currently, the analyst consensus on Antares Pharma is a Strong Buy with an average price target of $4.60, representing a 41.1% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRS:
